Fig. 4From: Primary cold atmospheric plasma combined with low dose cisplatin as a possible adjuvant combination therapy for HNSCC cells—an in-vitro studyCisplatin dose–response curve for Cal 27, FaDu and OSC 19 cells, IC50 and used concentration of 2.5 µM are displayedBack to article page